
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio is demonstrating great potential in the biopharmaceutical market by expanding their collaboration agreements and working on multiple promising drug candidates to address underserved medical conditions. With their focus on oral delivery, the company is creating convenient treatment options for patients and has shown successful results in their Phase 2 study for their EB612 program. The addition of Steve Rubin, a seasoned executive with experience in drug development, to the board of directors further strengthens Entera Bio's leadership team.
Bears say
Entera Bio is expected to enter the clinic soon with a next-generation formulation of EB613 that utilizes a refined version of its proprietary N-Tab formulation platform. Positive results from its Phase 1 trial could decrease pivotal clinical development risk and increase the commercial potential of this candidate. The pivotal program for EB613 is expected to begin later this year, with potential for regulatory approval and launch in 2029.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares